# Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

> **NCT03939026** · PHASE1 · COMPLETED · sponsor: **Allogene Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Relapsed/Refractory Large B Cell Lymphoma
- Relapsed/Refractory Follicular Lymphoma

## Interventions

- **GENETIC:** ALLO-501
- **BIOLOGICAL:** ALLO-647
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03939026
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2021-10-23
- **Final completion:** 2025-01-28
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939026, "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03939026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*